Adoptive immunotherapy for Hodgkin's lymphoma

Adoptive transfer of tumor-specific T-cells is an attractive strategy for the treatment of patients with refractory or relapsed Hodgkin's lymphoma. However, Hodgkin's lymphomas possess a range of tumor-evasion mechanisms, which must be overcome before the full potential of immunotherapies...

Full description

Saved in:
Bibliographic Details
Published in:International journal of hematology 2006-06, Vol.83 (5), p.385-390
Main Authors: Kennedy-Nasser, Alana A, Bollard, Catherine M, Rooney, Cliona M
Format: Article
Language:English
Subjects:
Cytokines - immunology
Epstein-Barr Virus Infections - immunology
Hodgkin Disease - immunology
Hodgkin Disease - therapy
Humans
Immunotherapy, Adoptive - methods
Lymphoma, Non-Hodgkin - immunology
Lymphoma, Non-Hodgkin - therapy
T-Lymphocytes, Cytotoxic - immunology
T-Lymphocytes, Cytotoxic - transplantation
Tumor Escape - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Adoptive transfer of tumor-specific T-cells is an attractive strategy for the treatment of patients with refractory or relapsed Hodgkin's lymphoma. However, Hodgkin's lymphomas possess a range of tumor-evasion mechanisms, which must be overcome before the full potential of immunotherapies can be achieved. In this article, we discuss the promise of Epstein-Barr virus-specific cytotoxic T-lymphocytes, the roles of cytokines, and other strategies for overcoming the immune-evasion mechanisms in Hodgkin's lymphoma.
ISSN:0925-5710
1865-3774
DOI:10.1532/IJH97.06107